Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Cognitive Function in Multiple Sclerosis
IRCT20210715051901N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine in multiple sclerosis (MS), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Cognitive function. Started Oct 2021; status: completed.
02
Drugs
atomoxetine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20210715051901N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210715051901N1.